Liver Breakthrough: Common Vitamin’s Secret Power

A hand reaching for a golden capsule among many on a table

A common vitamin hidden in your kitchen cabinet could reverse the silent liver epidemic affecting one in three people worldwide.

Story Highlights

Niacin (vitamin B3) suppresses key genetic driver miR-93, slashing fat buildup, inflammation, and scarring in fatty liver disease.
Researchers screened 150 FDA-approved drugs; niacin topped the list for safety and efficacy in mouse models and patient tissues.
MASLD strikes 30% globally, with no targeted treatments until this miRNA breakthrough offers cheap repurposing hope.
Gene-edited mice proved niacin restores metabolism, boosts insulin sensitivity, paving way for human trials.

Discovery of miR-93 as MASLD Driver

Professor Jang Hyun Choi at UNIST led a team from Pusan National University and Ulsan University Hospital. They analyzed patient liver samples and mouse models. MicroRNA-93 (miR-93) emerged as the central culprit accelerating metabolic-associated fatty liver disease (MASLD). This molecule disrupts SIRT1 activity, triggering lipid overload, inflammation, and fibrosis. Knocking out miR-93 in mice halted disease progression entirely. Their work marks the first clear mapping of this pathway.

Niacin Emerges as Top Suppressor

The team screened 150 FDA-approved drugs against miR-93. Niacin, or vitamin B3, outperformed all others. It directly curbs miR-93 expression, reactivates SIRT1, and normalizes lipid metabolism. Mouse experiments showed dramatic drops in liver fat and improved insulin response. Patient data confirmed the mechanism. Niacin’s decades-long safety record for cholesterol treatment makes it ideal for quick repurposing. Choi’s group calls it prime for combo therapies.

MASLD’s Global Crisis and Treatment Void

MASLD, formerly NAFLD, exploded since the 1980s alongside obesity. It now burdens 30% of adults worldwide, silently advancing to cirrhosis without warning. Lifestyle changes help mildly, but no drugs target the root. Genetic insights like miR-93 shift focus upstream. Current options chase symptoms like high blood sugar. This gap fuels urgency for accessible fixes. Lean cases, unrelated to weight, add complexity even for fit individuals.

Latest Advances and Parallel Paths

September 12, 2025, saw the niacin findings publish in Metabolism: Clinical and Experimental. Early 2026 brought vitamin D data showing L-shaped risk in lean NAFLD below 60 nmol/L. UConn’s Dr. Shi-Chao Zhong filed a patent March 3, 2026, for HNF4A-AS1 inhibitors via ASOs. Zhong predicts pharma disruption by hitting regulators early. Niacin remains preclinical, eyeing trials soon. Vitamin D urges simple screening.

• #Science #Physics #Chemistry #BioScience #Mathematics #Quantum #Nuclear #Engineering 🧬 •

» Fatty liver breakthrough: A common vitamin shows promise https://t.co/yK1QLP6F2j

— Tathagata M. (@tatha_gautama) March 25, 2026